
Apollo Endosurgery APEN
Annual report 2022
added 03-30-2023
Apollo Endosurgery General and Administrative Expenses 2011-2026 | APEN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Apollo Endosurgery
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.6 M | 18.4 M | 11.1 M | 13.6 M | 13.4 M | 13.7 M | 13.6 M | 3.95 M | 4.76 M | 4.23 M | 4.09 M | 3.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 M | 3.37 M | 10.4 M |
Quarterly General and Administrative Expenses Apollo Endosurgery
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 5.19 M | - | 5.23 M | - | 4.57 M | 5.34 M | 4.07 M | - | 2.37 M | 2.16 M | 3.34 M | - | 3.16 M | 3.34 M | 3.72 M | - | 3.02 M | 3.25 M | 3.32 M | - | 2.86 M | 3.25 M | 4.19 M | - | 3.84 M | 2.33 M | 2.64 M | - | 858 K | 1.1 M | 1.05 M | - | 1.05 M | 1.08 M | 1.16 M | - | 977 K | 1.11 M | 1 M | - | 1.07 M | 873 K | 882 K | - | 774 K | 794 K | 753 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.34 M | 753 K | 2.45 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Cognyte Software Ltd.
CGNT
|
163 M | $ 7.25 | -8.17 % | $ 521 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.97 | - | $ 137 M | ||
|
Alphatec Holdings
ATEC
|
450 M | $ 13.48 | -4.13 % | $ 1.93 B | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 4.08 | 0.37 % | $ 152 M | ||
|
Bio-Rad Laboratories
BIO
|
814 M | $ 299.07 | -2.23 % | $ 8.44 B | ||
|
Bruker Corporation
BRKR
|
894 M | $ 41.06 | -3.54 % | $ 6.12 K | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
5.98 B | $ 78.26 | 3.65 % | $ 115 B | ||
|
Abbott Laboratories
ABT
|
11.7 B | $ 109.11 | 0.84 % | $ 190 B | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
ClearPoint Neuro
CLPT
|
12 M | $ 12.43 | -6.61 % | $ 336 M | ||
|
CONMED Corporation
CNMD
|
117 M | $ 40.63 | 1.75 % | $ 1.25 B | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
39.3 M | $ 28.95 | -0.96 % | $ 245 M | ||
|
InMode Ltd.
INMD
|
8.41 M | $ 14.77 | -1.66 % | $ 1.17 B | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | ||
|
Profound Medical Corp.
PROF
|
10.3 M | $ 6.35 | -6.89 % | $ 180 M | ||
|
Align Technology
ALGN
|
1.76 B | $ 176.77 | 9.59 % | $ 13.2 B | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.54 | 0.11 % | $ 122 M | ||
|
Globus Medical
GMED
|
981 M | $ 87.55 | 0.56 % | $ 11.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 10.94 | -1.26 % | $ 842 M | ||
|
Establishment Labs Holdings
ESTA
|
140 M | $ 66.7 | -3.52 % | $ 1.88 B | ||
|
IRIDEX Corporation
IRIX
|
8.75 M | $ 1.45 | 0.69 % | $ 23.4 M | ||
|
IRadimed Corporation
IRMD
|
15.9 M | $ 94.23 | 0.4 % | $ 1.19 B | ||
|
Integer Holdings Corporation
ITGR
|
185 M | $ 85.94 | 0.49 % | $ 2.89 B | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Cytosorbents Corporation
CTSO
|
35 M | $ 0.67 | 0.3 % | $ 36.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
103 M | $ 16.64 | -1.54 % | $ 384 M |